News

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to…

2 years ago

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing…

2 years ago

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

2 years ago

NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on…

2 years ago

Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical…

2 years ago

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Conference call scheduled for 8:30 a.m. ET todayMIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or…

2 years ago

Acutus Medical completes enrollment in IDE trial with its AcQBlate® FORCE Sensing Ablation System

AcQBlate FORCE System A complete ablation system which includes the smallest footprint of any RF Generator and is comprised of…

2 years ago

Progressive Care to Report First Quarter Financial Results on May 17, 2022

Progressive Care Inc. Has Scheduled an Investor Conference Call for 4:30 PM ET on Tuesday, May 17, 2022 MIAMI, FL,…

2 years ago

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at…

2 years ago

ProSomnus® Presents Data Validating Proprietary FDA-cleared Oral Appliance Therapy Devices at 2022 American Academy of Dental Sleep Medicine Annual Meeting

Data suggest ProSomnus’s patient-preferred devices can be suitable alternative to CPAPSAN FRANCISCO, May 13, 2022 (GLOBE NEWSWIRE) -- ProSomnus, the…

2 years ago